Increasing the robustness and validity of RNAi screens

Pharmacogenomics

Volumn 8, Issue 8, 2007, Pages 1037-1049

  Haney, Steven A ^a  

^a PFIZER INC   (United States)

Author keywords

Drug development; HCS; High throughput; High content screening; MIARE; Oncology; RNAi; Screening; shRNA; siRNA; Statisticalanalysis; Target validation

Indexed keywords

MESSENGER RNA; MICRORNA; SMALL INTERFERING RNA;

CELL DIFFERENTIATION; CELL GROWTH; DATA ANALYSIS; DRUG RESEARCH; DRUG SENSITIVITY; GENE LIBRARY; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC TRANSFECTION; GENOTYPE PHENOTYPE CORRELATION; HIGH THROUGHPUT SCREENING; HUMAN; KNOCKOUT GENE; MAMMAL CELL; NONHUMAN; PROFESSIONAL STANDARD; REVIEW; RNA ANALYSIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; VALIDATION PROCESS;

ANIMALS; GENE LIBRARY; GENETIC SCREENING; HUMANS; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE;

MAMMALIA;

EID: 34548740266     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.8.1037     Document Type: Review

References (77)

1. Bernards R, Brummelkamp TR, Beijersbergen RL: shRNA libraries and their use in cancer genetics. Nat. Methods 3, 701-706 (2006).
2. Echeverri CJ, Perrimon N: High-throughput RNAi screening in cultured cells: a user's guide. Nat. Rev. Genet. 7, 373-384 (2006).
3. Moffat J, Grueneberg DA, Yang X et al.: A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124, 1283-1298 (2006).
4. Perrimon N, Mathey-Prevot B: Applications of high-throughput RNA interference screens to problems in cell and developmental biology. Genetics 175, 7-16 (2007).
5. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R: Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424, 797-801 (2003).
6. Chatterjee-Kishore M: From genome to phenome - RNAi library screening and hit characterization using signaling pathway analysis. Curr. Opin. Drug Discov. Devel. 9, 231-239 (2006).
7. Whitehurst AW, Bodemann BO, Cardenas J et al.: Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446, 815-819 (2007).
8. Swanton C, Marani M, Pardo O et al.: Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11, 498-512 (2007).
9. Brazma A, Krestyaninova M, Sarkans U: Standards for systems biology. Nat. Rev. Genet. 7, 593-605 (2006).
10. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK: Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2, 458-466 (2006).
11. Janes KA, MB Yaffe: Data-driven modelling of signal-transduction networks. Nat. Rev. Mol. Cell Biol. 7(11), 820-828 (2006).
12. Butcher EC, Berg EL, Kunkel EJ: Systems biology in drug discovery. Nat. Biotechnol. 22, 1253-1259 (2004).
13. Swedlow JR, Lewis SE, Goldberg IG: Modelling data across labs, genomes, space and time. Nat. Cell Biol. 8(11), 1190-1194 (2006).
14. Stromback L, Hall D, Lambrix P: A review of standards for data exchange within systems biology. Proteomics 7, 857-867 (2007).
15. Jackson AL, Bartz SR, Schelter J et al.: Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21, 635-637 (2003).
16. Bernstein E, Caudy AA, Hammond SM, Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409, 363-366 (2001).
17. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD: A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293, 834-838 (2001).
18. Ketting RF, Fischer SE, Bernstein E et al.: Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 15, 2654-2659 (2001).
19. Liu Q, Rand TA, Kalidas S et al.: R2D2, a bridge between the initiation and effector steps of the Drosophila RNAi pathway. Science 301, 1921-1925 (2003).
20. Tomari Y, Matranga C, Haley B, Martinez N, Zamore PD: A protein sensor for siRNA asymmetry. Science 1377-1380 (2004).
21. Liu J, Carmell MA, Rivas FV et al.: Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437-1441 (2004).
22. Collins RE, Cheng X: Structural domains in RNAi. FEBS Lett. 579, 5841-5849 (2005).
23. Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS: Post-transcriptional gene silencing by siRNAs and miRNAs. Curr. Opin. Struct. Biol. 15, 331-341 (2005).
24. Paroo Z, Liu Q, Wang X: Biochemical mechanisms of the RNA-induced silencing complex. Cell Res. 17, 187-194 (2007).
25. Okamura K, Ishizuka A, Siomi H, Siomi MC et al.: Distinct roles for Argonaute proteins in small RNA-directed RNA cleavage pathways. Genes Dev. 18, 1655-1666 (2004).
26. Elbashir SM, Harborth J, Weber K, Tuschl T: Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26(2), 199-213 (2002).
27. Hsieh AC, Bo R, Manola J et al.: A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Res. 32, 893-901 (2004).
28. Khvorova A, Reynolds A, Jayasena SD: Functional siRNAs and miRNAs exhibit strand bias. Cell 115, 209-216 (2003).
29. Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD: Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199-208 (2003).
30. Jackson AL, Burchard J, Schelter J et al.: Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12, 1-9 (2006).
31. Birmingham A, Zheng GX, Burge CB, et al.: 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 3, 199-204 (2006).
32. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16(8), 948-958 (2002).
33. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 296(5567), 550-553 (2002).
34. Yu JY, DeRuiter SL, Turner DL: RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Natl Acad. Sci. USA 99(9), 6047-6052 (2002).
35. Stegmeier F. Hu G, Rickles RJ, Hannon GJ, Elledge SJ: A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc. Natl. Acad Sci. USA 102, 13212-13217 (2005).
36. Silva JM, Li MZ, Chang K et al.: Second-generation shRNA libraries covering the mouse and human genomes. Nat. Genet. 37, 1281-1288 (2005).
37. Grimm D, Streetz KL, Jopling CL et al.: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (2006).
38. Henriksen JR, Løkke C, Hammerø M et al.: Comparison of RNAi efficiency mediated by tetracycline-responsive H1 and U6 promoter variants in mammalian cell lines. Nucleic Acids Res. (2007) (In Press).
39. Kappel S, Matthess Y, Zimmer B, Kaufmann M, Strebhardt K: Tumor inhibition by genomically integrated inducible RNAi-cassettes. Nucleic Acids Res. 34, 4527-4536 (2006).
40. Aagaard L, Amarzguioui M, Sun G et al.: A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha. Mol. Ther. (2007) (In Press).
41. Kolfschoten IG, van Leeuwen B, Berns K et al.: A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 121, 849-858 (2005).
42. Westbrook TF, Martin ES, Schlabach MR et al.: A genetic screen for candidate tumor suppressors identifies REST. Cell 121, 837-848 (2005).
43. Brummelkamp TR, Fabius AW, Mullenders J et al.: An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol. 2, 202-206 (2006).
44. Kittler R, Putz G, Pelletier L et al.: An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature 432, 1036-1040 (2004).
45. Kittler R, Surendranath V, Heninger AK et al.: Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. Nat. Methods 4, 337-344 (2007).
46. Wiemann S: MIACA-Minimum Information About a Cellular Assay, and the Cellular Assay Object Model. Nat. Biotechnol. (2007). (In press)
47. Echeverri CJ, Beachy PA, Baum B et al.: Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat. Methods 3, 777-779 (2006).
48. Huppi K, Martin SE, Caplen NJ: Defining and assaying RNAi in mammalian cells. Mol Cell. 17, 1-10 (2005).
49. Sorlie T, Tibshirani R, Parker J et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-8423 (2003).
50. Brazma A, Hingamp P, Quackenbush J et al.: Minimum information about a microarray experiment (MIAME) - toward standards for microarray data. Nat. Genet. 29, 365-371 (2001).
51. Zhang JH, Chung TDY, Oldenberg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73 (1999).
52. Boutros M, Bras LP, Huber W: Analysis of cell-based RNAi screens. Genome Biol. 7, 66 (2006).
53. Swedlow JR, Goldberg I, Brauner E, Sorger PK: Informatics and quantitative analysis in biological imaging. Science 300, 100-102 (2003)
54. Dunlay RT, Czekalski WJ, Collins MA: Overview of informatics for high content screening. Methods Mol. Biol. 356, 269-280 (2007).
55. Garfinkel LS: Large-scale data management for high content screening. Methods Mol. Biol. 356, 281-291 (2007).
56. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R: Statistical practice in high-throughput screening data analysis. Nat. Biotechnol. 24(2), 167-175 (2006).
57. Walters WP, Namchuk M: Designing screens: how to make your hits a hit. Nat. Rev. Drug. Discov. 2, 259-266 (2003).
58. Majercak J, Ray WJ, Espeseth A et al.: LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. Proc. Natl Acad. Sci. USA 21, 17967-17972 (2006).
59. Stone DJ, Marine S, Majercak J et al.: High-throughput screening by RNA interference: control of two distinct types of variance. Cell Cycle 6, 898-901 (2007).
60. Zhang XD: A pair on new statistical parameters for quality control in RNA interference high-throughput screening assays. Genomics 89, 552-561 (2007).
61. Zhang XD, Ferrer M, Espeseth AS et al.: The use of strictly standardized mean difference for hit selection in primary RNA interference high-throughput screening experiments. J. Biomiol. Screen. (2007) (Epub ahead of print).
62. Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH: Delivery of RNAi interference. Cell Cycle 5, 2103-2109 (2006).
63. Lipinski CA: Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235-249 (2000).
64. Giuliano KA, Chen YT, Taylor DL: High-content screening with siRNA optimizes a cell biological approach to drug discovery: defining the role of p53 activation in the cellular response to anticancer drugs. J. Biomol. Screen. 9, 557-568 (2004).
65. Irish JM, Hovland R, Krutzik PO et al.: Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118, 217-228 (2004).
66. Loo LH, Wu LF, Altschuler SJ: Image-based multivariate profiling of drug responses from single cells. Nat. Methods 4, 445-453. (2007).
67. Perlman ZE, Slack MD, Feng Y, Mitchison TJ, Wu LF, Altschuler SJ: Multidimensional drug profiling by automated microscopy. Science 306(5699) 1194-1198 (2004).
68. Jaqaman K, Danuser G: Linking data to models: data regression. Nat. Rev. Mol. Cell Biol. 7(11), 813-819 (2006).
69. Adams CL, Kutsyy V, Coleman DA et al.: Compound classification using image-based cellular phenotypes. In: Methods in Enzymology: Measuring Biological Responses with Automated Microscopy. Inglese J (Ed.). Academic Press, Oxford, UK, 440-468 (2006).
70. Tan PK, Downey TJ, Spitznagel EL et al.: Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res. 31, 5676-5684 (2003).
71. Draghici S, Khatri P, Eklund AC, Szallasi Z: Reliability and reproducibility issues in DNA microarray measurements. Trends Genet. 22, 101-109 (2006).
72. Bammler T, Beyer RP, Bhattacharya S et al.; Members of the Toxicogenomics Research Consortium: Standardizing global gene expression analysis between laboratories and across platforms. Nat. Methods 2, 351-356 (2005).
73. Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J: Independence and reproducibility across microarray platforms. Nat. Methods 2, 377-344 (2005).
74. Irizarry RA, Warren D, Spencer F et al.: Multiple-laboratory comparison of microarray platforms. Nat. Methods 2, 345-350 (2005).
75. MAQC Consortium; Shi L, Reid LH, Jones WD et al.: The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24, 1151-1161 (2006).
76. Lin G, He X, Ji H, Shi L, Davis RW, Zhong S: Reproducibility Probability Score - incorporating measurement variability across laboratories for gene selection. Nat. Biotechnol. 24, 1476-1477 (2006).
77. Strauss E: Arrays of hope. Cell 127, 657-659 (2006).